Curis, Debiopharm Group Reports Debio 0932 Demonstrated Anti-Tumor Activity
April 07, 2014 at 16:29 PM EDT
Curis, Inc. (Nasdaq: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, ...